Alzheimer's Disease- Drug Pipeline Landscape, 2023

Alzheimer's Disease- Drug Pipeline Landscape, 2023

Alzheimer's disease is a progressive, degenerative brain disorder that attacks the brain's nerve cells, or neurons, and causes them to waste away. This disease is characterized by a slow, gradual decline in memory, thinking, and reasoning skills. Alzheimer's is the most common form of dementia, accounting for 60 to 80 percent of all cases. Dementia is a general term for a decline in mental ability severe enough to interfere with daily life.

Alzheimer's disease is named after German physician Alois Alzheimer. In 1906, Dr. Alzheimer noticed changes in the brain tissue of a patient who had died of an unusual mental illness. He found abnormal clumps (now called amyloid plaques) and tangled bundles of fibers (now called neurofibrillary tangles) among the patient's brain cells. These discoveries provide some of the first hints about what happens in the brains of people with Alzheimer's.

Scientists now know that the plaques and tangles are made up of specific proteins that build up in and around brain cells. These proteins damage and kill brain cells. As more brain cells die, connections among cells are lost. This process starts slowly, but over time, it spreads throughout the brain.

Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. The disease severely affects memory, thinking, learning and organizing skills and eventually affects a person's ability to carry out simple daily activities.

The exact cause of Alzheimer's is unknown but there are certain risk factors like age, family history, genetics, depression, smoking and cardiovascular disease.

Symptoms of the disease include memory loss, putting objects in odd places, confusion about events, time and place, repeating questions, trouble managing money and paying bills, trouble performing/taking longer to perform familiar tasks, setting lost/wandering, not being able to sleep, changes in personality and behavior including agitation, anxiety and aggression.

Diagnostic tests for Alzheimer's disease include evaluation of medical history, blood and urine tests, mental status testing, neuropsychological testing, brain imaging tests like computered tomography, magnetic resonance imaging, and positron emission tomography.

Alzheimer's disease has is no cure, medications temporarily slow the worsening of dementia symptoms and help with behavioral problems that may appear. Treatment of Alzheimer's disease include cholinesterase inhibitors like donepezil, rivastigmine, galantamine; NMDA antagonist like memantine.

There are many clinical trials currently ongoing in Alzheimer's disease drug development. Some of the most promising trials are studying new ways to treat the disease, such as by targeting specific proteins that are thought to be involved in the development of Alzheimer's. Other trials are studying new drugs that may help to improve symptoms or slow the progression of the disease. still others are investigating new ways to diagnose Alzheimer's early, before symptoms begin.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Alzheimer’s Disease treatment such as Donanemab, Lecanemab, E2814, Gantenerumab, LY3372993, ABBV-916, Canakinumab and others. Key players involved in the development of therapies to treat Alzheimer’s Disease are Eli Lilly and Company, Hoffmann-La Roche, Eisai Inc, AbbVie, Novartis Pharmaceuticals and others. Two drugs are under late-stage pre-registration, 20+ drugs are under phase III clinical trials and 50+ drugs are in Phase II clinical trials and some other drugs are under Phase I, Phase 0, Preclinical, Discovery and unknown stages of development.

In November 2022, Eli Lilly and Company has announced that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis in the phase 3 TRAILBLAZER-ALZ 4 study, providing the first active comparator data on amyloid plaque clearance in patients with early symptomatic alzheimer's disease treated with amyloid-targeting therapies.

In November 2022, Eisai presented full results of Lecanemab phase 3 confirmatory clarity AD study for early alzheimer’s disease at Clinical Trials on Alzheimer’s Disease (CTAD) conference.

Report Highlights

Global Insight Service's, Alzheimer's Disease - Drug Pipeline Landscape, 2023 report provides an overview of the Alzheimer's Disease pipeline drugs. This report covers detailed insights on Alzheimer's Disease drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Alzheimer's Disease pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.